Aripiprazole for the Management of Schizophrenia in the Japanese Population: a Systematic Review and Meta-analysis of Randomized Controlled Trials

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2015 Mar 12

PMID 25759585

Citations 4

Authors

Taro Kishi

Yuki Matsuda

Shinji Matsunaga

Nakao Iwata

Affiliations

Soon will be listed here.

Abstract

Background: We conducted a systematic review and meta-analysis of randomized controlled trials comparing aripiprazole with pooled antipsychotics in Japanese patients with schizophrenia.

Methods: We performed a literature search of data published in PubMed(®), the Cochrane Library database, the Japan Medical Abstracts Society, and PsycINFO(®) up to January 5, 2014. The odds ratio (OR), number-needed-to-harm (NNH), and standardized mean difference (SMD) based on a random effects model were calculated.

Results: We identified five relevant studies (seven comparisons, n=684; one comparison each for haloperidol [n=243], mosapramine [n=238], olanzapine [n=39], quetiapine [n=42], perospirone [n=100], and two comparisons for risperidone [n=66]). There were no significant differences in the Positive and Negative Syndrome Scale (PANSS) total, negative, and general scores (SMD=0.10, SMD=-0.09, SMD=0.10, respectively); discontinuation rate associated with all causes (OR=1.35); or side effects (OR=1.03) between aripiprazole and the pooled antipsychotics. Aripiprazole was inferior to the pooled antipsychotics in PANSS positive subscale scores (SMD=0.17) and discontinuation because of inefficacy (OR=2.21, NNH=11). However, aripiprazole had fewer side effects compared with the pooled antipsychotics (OR=0.21, NNH=20 for one or more side effects), including fatigue (OR=0.22, NNH=8), hyperprolactinemia (OR=0.00, NNH=1), extrapyramidal symptoms (OR=0.46, NNH=6), and weight gain (OR=0.36, NNH=7). Moreover, aripiprazole was associated with lower total cholesterol (SMD=-0.20) and triglyceride (SMD=-0.17) levels and body weight (SMD=-0.20) compared with the pooled antipsychotics.

Conclusion: Although the discontinuation rate associated with inefficacy was higher with aripiprazole than with the pooled antipsychotics, aripiprazole was associated with a lower risk of hyperprolactinemia and metabolic and extrapyramidal symptoms compared with the pooled antipsychotics.

Citing Articles

Efficacy and Side Effects of Aripiprazole and Olanzapine in Patients with Psychotic Disorders: A Randomized Controlled Trial.

Ghitoli N, Rezaie L, Elahi A Oman Med J. 2024; 38(5):e553.

PMID: 38249132 PMC: 10800020. DOI: 10.5001/omj.2023.109.

Early non-response as a predictor of later non-response to antipsychotics in schizophrenia: a randomized trial.

Long Y, Wu Q, Yang Y, Cai J, Xiao J, Liu Z BMC Med. 2023; 21(1):263.

PMID: 37468932 PMC: 10354903. DOI: 10.1186/s12916-023-02968-7.

Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure.

Kiss A, Menus A, Toth K, Deri M, Sirok D, Gabri E Eur Arch Psychiatry Clin Neurosci. 2019; 270(1):71-82.

PMID: 30604050 DOI: 10.1007/s00406-018-0975-2.

Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review.

Yin J, Barr A, Ramos-Miguel A, Procyshyn R Curr Neuropharmacol. 2016; 15(1):174-183.

PMID: 27264948 PMC: 5327459. DOI: 10.2174/1570159x14666160606093602.

References

Kuipers E, Yesufu-Udechuku A, Taylor C, Kendall T . Management of psychosis and schizophrenia in adults: summary of updated NICE guidance. BMJ. 2014; 348:g1173. DOI: 10.1136/bmj.g1173. View

Inada T, Yagi G, Miura S . Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr Res. 2002; 57(2-3):227-38. DOI: 10.1016/s0920-9964(01)00314-0. View

Mulligan M, Vasu R, Grossi C, Prasthofer E, Griffin Jr F, Kapila A . Neoplastic meningitis with eosinophilic pleocytosis in Hodgkin's disease: a case with cerebellar dysfunction and a review of the literature. Am J Med Sci. 1988; 296(5):322-6. DOI: 10.1097/00000441-198811000-00005. View

Buchanan R, Kreyenbuhl J, Kelly D, Noel J, Boggs D, Fischer B . The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2009; 36(1):71-93. PMC: 2800144. DOI: 10.1093/schbul/sbp116. View

Danaei G, Finucane M, Lu Y, Singh G, Cowan M, Paciorek C . National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet. 2011; 378(9785):31-40. DOI: 10.1016/S0140-6736(11)60679-X. View

Yoon K, Lee J, Kim J, Cho J, Choi Y, Ko S . Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006; 368(9548):1681-8. DOI: 10.1016/S0140-6736(06)69703-1. View

Khanna P, Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, El-Sayeh H . Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013; (2):CD006569. DOI: 10.1002/14651858.CD006569.pub4. View

Correll C, Manu P, Olshanskiy V, Napolitano B, Kane J, Malhotra A . Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009; 302(16):1765-73. PMC: 3055794. DOI: 10.1001/jama.2009.1549. View

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

10.

Malhotra A, Correll C, Chowdhury N, Muller D, Gregersen P, Lee A . Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry. 2012; 69(9):904-12. PMC: 4166499. DOI: 10.1001/archgenpsychiatry.2012.191. View

11.

Slomko H, Heo H, Einstein F . Minireview: Epigenetics of obesity and diabetes in humans. Endocrinology. 2012; 153(3):1025-30. PMC: 3281541. DOI: 10.1210/en.2011-1759. View

12.

Sone H, Ito H, Ohashi Y, Akanuma Y, Yamada N . Obesity and type 2 diabetes in Japanese patients. Lancet. 2003; 361(9351):85. DOI: 10.1016/S0140-6736(03)12151-4. View

13.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339:b2535. PMC: 2714657. DOI: 10.1136/bmj.b2535. View

14.

Stauffer V, Sniadecki J, Piezer K, Gatz J, Kollack-Walker S, Poole Hoffmann V . Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder. BMC Psychiatry. 2010; 10:89. PMC: 3020682. DOI: 10.1186/1471-244X-10-89. View

15.

Kimura G, Kadoyama K, Brown J, Nakamura T, Miki I, Nisiguchi K . Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database. Int J Med Sci. 2015; 12(2):135-40. PMC: 4293178. DOI: 10.7150/ijms.10453. View

16.

Sato G, Yoshimura S, Yamashita H, Okamoto Y, Yamawaki S . The neurocognitive effects of aripiprazole compared with risperidone in the treatment of schizophrenia. Hiroshima J Med Sci. 2013; 61(4):75-83. View

17.

Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Asenjo Lobos C . Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010; 123(2-3):225-33. PMC: 2957510. DOI: 10.1016/j.schres.2010.07.012. View

18.

Mattila T, Wohlfarth T, Koeter M, Storosum J, van den Brink W, de Haan L . Geographic variation in efficacy of atypical antipsychotics for the acute treatment of schizophrenia - an individual patient data meta-analysis. Eur Neuropsychopharmacol. 2014; 24(7):1067-77. DOI: 10.1016/j.euroneuro.2014.02.006. View

19.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

20.

Choi J, Yoo H . Control of puberty: genetics, endocrinology, and environment. Curr Opin Endocrinol Diabetes Obes. 2012; 20(1):62-8. DOI: 10.1097/MED.0b013e32835b7ec7. View